Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

Blood. 2006 Jul 1;108(1):403; author reply 404. doi: 10.1182/blood-2006-01-0154.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Aspirin / therapeutic use*
  • Dexamethasone / adverse effects*
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Lenalidomide
  • Multiple Myeloma* / complications
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / drug therapy
  • Risk Factors
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives*
  • Thromboembolism / chemically induced
  • Thromboembolism / drug therapy
  • Thromboembolism / prevention & control*
  • Thrombosis / chemically induced
  • Thrombosis / drug therapy
  • Thrombosis / prevention & control*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Thalidomide
  • Dexamethasone
  • Lenalidomide
  • Aspirin